Jincheng Pharmaceutical (300233.SZ) announced first-half results, with net profit of 139 million yuan to mother, an increase of 220.11% over the previous year

According to the Zhitong Finance App, Jincheng Pharmaceutical (300233.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 1,447 billion yuan, an increase of 6.40% over the previous year. Achieved net profit of 139 million yuan attributable to shareholders of listed companies, an increase of 220.11% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 66.99,900 yuan, an increase of 70.92% over the previous year. Basic earnings per share were $0.37.

During the reporting period, the company continued to improve the organizational structure and optimize the “three-level” integrated operation system of strategic management headquarters, professional divisions and lean factories. During the reporting period, the effectiveness of the company's division system continued to be released, the CXO division was added, and a service circuit for the entire pharmaceutical industry chain was laid out. The specialized division of labor in the division system has significantly improved the specialized management capabilities and operational collaboration efficiency of various industrial sectors. The division is deeply linked with the production plant, and the synergy effect of integrating R&D, production, supply and marketing has been fully demonstrated, and the quality and efficiency of industrial operation has been steadily improved; the efficiency of the business development (BD) line continues to be released, and an internal coordination mechanism for resource sharing, information joint research, and efficient linkage has been established.